Predilution online hemodiafiltration with Citrasate - is it a possible option for heparin free procedure?
Citrate acid concentrate Citrasate for online predilution hemodiafiltration in patients on maintenance hemodialysis as an alternative of anticoagulation free procedure - comparison with acetate-based concentrate.
Pavlina Richtrova, M.D., Ph.D.
10 participants
Sep 13, 2013
Interventional
Conditions
Summary
We want to test the hypothesis, 4 hr online predilution HDF with Citrasate is possible to be realized without manifest clotting problems even with no anticoagulation therapy. As a secondary outcome we want to describe coagulation cascade activation based on TAT concentration during this HDF procedure.
Eligibility
Inclusion Criteria2
- chronic kidney disease 5/5 K/DOQI, more than 3 months on maintenance dialysis treatment,
- native arteriovenous fistula with blood flow at least 300 ml/min.
Exclusion Criteria4
- laboratory markers of hepatopathy ( = ALT and AST more than double of upper borderline lab value),
- hemostasis disorder ( = pathological value of prothrombin time and aPTT and thrombocyte count less than 100 000/ul),
- antithrombotic treatment excluding acetylsalicylic acid (aspirin)
- malignancy
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
In a random order patients undergo one 4 hr procedure of online predilution hemodiafiltration with acetic acid or citrate acid (Citrasate) concentrate respectively. In two weeks and in a cross-over manner they undergo the second study procedure with citrate or acetic acid respectively. Citrate concentration in Citrasate is 0,8 mmol/l.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12613001117707